Merrimack Pharmaceuticals Inc.

258 articles with Merrimack Pharmaceuticals Inc.

• Merrimack Receives $5 Million Milestone Payment from Shire

  9/20/2018

  Merrimack Pharmaceuticals, Inc. today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack's asset sale to Ipsen in 2017.

• Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)

  9/6/2018

  Merrimack Pharmaceuticals, Inc. today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead investigational drug candidate, MM-121, in patients with heregulin positive NSCLC.

• 

  SEC Aims Insider Trading Charges at Former Sangamo Therapeutics Executive

  8/24/2018

  The U.S. Securities and Exchange Commission has leveled charges at a former Sangamo Therapeutics Inc. executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”

• Merrimack Reports Second Quarter 2018 Financial Results

  8/7/2018

  $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources

• 

  Former Akebia and Merrimack Employees Convicted of Insider Trading

  7/11/2018

  Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals (MACK) were convicted of insider trading by a federal grand jury in Boston.

• Merrimack Secures $25 Million Debt Facility with Hercules Capital

  7/2/2018

  Non-dilutive financing strengthens cash positio

• 

  3 Clinical Trials with Mixed to Disastrous Results: Sophiris, Merrimack and Pfizer

  6/25/2018

  Although it’s great to report on successful clinical trial results, the reality is that only about one in 10 drugs make it to approval. With that number in mind, here are a couple companies reporting problematic clinical trials today.

• Gemini Therapeutics Strengthens Senior Leadership Team with Key Appointments and Promotion

  5/30/2018

  Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.

• Merrimack Announces Timing of First Quarter 2018 Investor Conference Call

  5/1/2018

  Merrimack Pharmaceuticals, Inc. announced that the company will host its first quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, May 8, 2018.

• 

  Merrimack Pharmaceuticals Expands Phase II Lung Cancer Study

  3/12/2018

  Merrimack Pharmaceuticals announced it is expanding enrollment in a Phase II lung cancer study.

• Merrimack Provides Business Update and Reports 2017 Financial Results

  3/12/2018

  Merrimack Pharmaceuticals Inc. announced its fourth quarter and full year 2017 financial results for the period ended December 31, 2017.

• Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer

  3/12/2018

  Randomized Phase 2 study accrual raised to 100 patients; data still expected later this year.

• Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer

  2/26/2018

  MM-121 is a fully human monoclonal antibody that targets HER3 signaling and is designed to overcome cancer cells' resistance to the effects of anti-tumor therapies.

• 

  5 Massachusetts Biotechs That Tanked More Than 60% in 2017

  1/2/2018

  This is definitely a list few, if any, companies want to be on.

• Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors

  11/30/2017

  Dr. Demetri, a world-renowned expert in the clinical translation of innovative treatment strategies for cancer, replaces John Mendelsohn, M.D., who is retiring from the Board.

• Merrimack Reports Third Quarter 2017 Financial Results

  11/8/2017

  Merrimack today announced its third quarter 2017 financial results for the period ended September 30, 2017.

• Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call

  11/1/2017

  The call will cover an update on Merrimack's recent progress as well as a summary of third quarter 2017 financial results.

• Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-Small Cell Lung Cancer

  10/30/2017

  Merrimack today announced that the FDA has granted orphan drug designation to MM-121, its investigational drug candidate, a fully human monoclonal antibody.

• Merrimack Commences Tender Offer For Any And All Of Its Outstanding 4.50% Convertible Senior Notes Due 2020

  10/13/2017

• Merrimack Announces Settlement of Convertible Note Litigation

  10/11/2017